| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000005585 |
| Receipt No. | R000006512 |
| Official scientific title of the study | Dose-escalation study of proton beam therapy with chemotherapy for locally advanced non-small lung cancer |
| Date of disclosure of the study information | 2011/05/12 |
| Last modified on | 2016/04/23 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Dose-escalation study of proton beam therapy with chemotherapy for locally advanced non-small lung cancer | |
| Title of the study (Brief title) | Proton beam therapy dose escalation for NSCLC | |
| Region |
|
|
| Condition | |||
| Condition | Unresectable Non-small Lung Cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To define the recommended dose of proton beam therapy concurrent with chemotherapy for unresectable non-small lung cancer |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase I |
| Assessment | |
| Primary outcomes | To determine maximum torrelated dose and recommended dose |
| Key secondary outcomes | Adverse event
Tumor response survival rate |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | Proton beam therapy 66-74 GyE
(Cisplatin 60mg/m2 + TS-1 40mg d1-d4) |
||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Histologically proven Non-small lung cancer, Stage IIIA-IIIB
ECOG PS 0-1 Tumor size was measured by 4 wks before registration Good organ function |
|||
| Key exclusion criteria | Drug allergy
Active infection Lymph node metastasis at contra-lateral hiller, supraclavicular region. P Severe complication Apparent interstitial pneumonitis |
|||
| Target sample size | 12 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroshi Fuji |
| Organization | Shizuoka Cancer Center |
| Division name | Division of Proton therapy |
| Address | 1007 Shimonagakubo, Nagaizumi-cho, Shizuoka-pref. |
| TEL | 055-989-5222 |
| Public contact | |
| Name of contact person | Hiroshi Fuji |
| Organization | Shizuoka Cancer Center |
| Division name | Division of Proton therapy |
| Address | 1007 Shimonagakubo, Nagaizumi-cho, Shizuoka-pref. |
| TEL | 055-989-5222 |
| Homepage URL | |
| h.fuji@scchr.jp | |
| Sponsor | |
| Institute | Shizuoka Cancer Center |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 静岡県立静岡がんセンター(静岡県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006512 |